MONISTAT 3 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT 3 COMBINATION PACK (MONISTAT 3 COMBINATION PACK).
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Primarily hepatic via oxidative pathways; no specific CYP enzymes identified. |
| Excretion | Miconazole is primarily eliminated via hepatic metabolism with biliary excretion of metabolites; <1% of unchanged drug is excreted renally. Fecal elimination accounts for approximately 20-30% of the dose. |
| Half-life | After intravenous administration, the terminal elimination half-life is approximately 20-24 hours; after topical or intravaginal administration, systemic absorption is minimal, with a terminal half-life of 8-12 hours. |
| Protein binding | Miconazole is approximately 88-92% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | The apparent volume of distribution (Vd) is approximately 1.4-1.7 L/kg, indicating extensive tissue distribution beyond body water, with penetration into skin, vaginal mucosa, and inflamed tissues. |
| Bioavailability | Systemic bioavailability after intravaginal administration is extremely low (approximately 1-2%) due to poor mucosal absorption; after topical application, systemic absorption is negligible (<1%). |
| Onset of Action | For intravaginal miconazole, clinical improvement (relief of symptoms) typically begins within 24-72 hours due to local antifungal activity; for topical formulations, relief of dermatophyte infections may occur within 1-2 weeks. |
| Duration of Action | Intravaginal miconazole cream: sustained local concentrations persist for 24-72 hours after a single dose; the combination pack provides therapy for 3 days. Topical formulations: require once-daily application for 2-4 weeks depending on the indication. |
| Molecular Weight | 416.13 |
Insert one miconazole nitrate 200 mg vaginal suppository intravaginally once daily at bedtime for 3 consecutive days. Apply intravaginal cream as needed for symptom relief.
| Dosage form | CREAM, SUPPOSITORY |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for children under 12 years of age. |
| Geriatric use | Use as directed for adults; no specific adjustments for elderly. |
| 1st trimester | Generally considered safe; no increased risk of major malformations reported. Use only if clearly needed. |
| 2nd trimester | Generally considered safe; use only if clearly needed. |
| 3rd trimester | Generally considered safe; avoid use near term due to theoretical risk of premature labor. |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT 3 COMBINATION PACK (MONISTAT 3 COMBINATION PACK).
| Placental transfer | Minimal; following vaginal administration, systemic absorption is low (1-4%). Placental transfer is expected to be negligible. |
| Breastfeeding | Miconazole is poorly absorbed after topical application; systemic levels are minimal. It is considered compatible with breastfeeding. Avoid application to the breast area if infant may contact. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to miconazole or any componentage <12 years (for OTC use)
| Precautions | Do not use if allergic to any ingredient; discontinue if irritation occurs; avoid intravaginal use during menstruation; do not use if symptoms persist beyond 7 days; pregnancy category C; not for use in children under 12 unless directed by a doctor. |
| Food/Dietary | No significant food interactions. Limited grapefruit juice effect; however, miconazole is a CYP2C9 and CYP3A4 inhibitor, potentially affecting metabolism of certain drugs (e.g., warfarin, oral hypoglycemics). No dietary restrictions. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L2 |
| Teratogenic Risk | FDA Pregnancy Category C. Miconazole is generally not teratogenic in animal studies; however, there are no adequate and well-controlled studies in pregnant women. First trimester: use only if clearly needed and potential benefit justifies risk. Second and third trimesters: generally considered safe for intravaginal use; systemic absorption is minimal; however, avoid during first trimester unless essential. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care. Monitor for signs of local irritation or hypersensitivity; if systemic adverse effects occur, assess liver function and CBC. |
| Fertility Effects | No adverse effects on fertility have been reported. Miconazole does not impair fertility in animal studies. In humans, no data suggest an impact on fertility. |
| MONISTAT 3 COMBINATION PACK contains miconazole nitrate and miconazole nitrate vaginal suppositories. For intravaginal use only. Concomitant use of vaginal contraceptive diaphragms or condoms may reduce efficacy of those devices. Oil-based suppositories may weaken latex condoms or diaphragms. If patient is on warfarin, monitor INR due to potential CYP inhibition. Avoid use in pregnant patients unless benefit outweighs risk; use only during second or third trimester with caution. Do not use if patient has abdominal pain, fever, foul-smelling discharge, or is under 12 years of age without medical consult. |
| Patient Advice | Use the vaginal cream and suppositories at bedtime for 3 consecutive nights. · Do not use tampons, douches, spermicides, or other vaginal products during treatment. · Avoid sexual intercourse during treatment to prevent further irritation and breakage of condoms or diaphragms. · If symptoms persist for more than 7 days or recur within 2 months, consult a doctor. · Wash hands before and after each application. · Do not use if you have abdominal pain, fever, or chills; seek medical attention. · Do not use during menstruation; wait until period ends before starting treatment. · Discontinue and consult doctor if you experience vaginal itching, burning, or rash. |